In vitro and in vivo antibacterial properties of peptide AMC-109 impregnated wound dressings and gels.


Journal

The Journal of antibiotics
ISSN: 1881-1469
Titre abrégé: J Antibiot (Tokyo)
Pays: England
ID NLM: 0151115

Informations de publication

Date de publication:
05 2021
Historique:
received: 03 11 2020
accepted: 24 12 2020
revised: 16 11 2020
pubmed: 27 1 2021
medline: 1 10 2021
entrez: 26 1 2021
Statut: ppublish

Résumé

Synthetic mimics of antimicrobial peptides (AMPs) is a promising class of molecules for a variety of antimicrobial applications. Several hurdles must be passed before effective systemic infection therapies with AMPs can be achieved, but the path to effective topical treatment of skin, nail, and soft tissue infections appears less challenging to navigate. Skin and soft tissue infection is closely coupled to the emergence of antibiotic resistance and represents a major burden to the healthcare system. The present study evaluates the promising synthetic cationic AMP mimic, AMC-109, for treatment of skin infections in vivo. The compound is evaluated both in impregnated cotton wound dressings and in a gel formulation against skin infections caused by Staphylococcus aureus and methicillin resistant S. aureus. Both the ability to prevent colonization and formation of an infection, as well as eradicate an ongoing infection in vivo with a high bacterial load, were evaluated. The present work demonstrates that AMC-109 displays a significantly higher antibacterial activity with up to a seven-log reduction in bacterial loads compared to current clinical standard therapy; Altargo cream (1% retapamulin) and Fucidin cream (2% fusidic acid) in the in vivo wound models. It is thus concluded that AMC-109 represents a promising entry in the development of new and effective remedies for various skin infections.

Identifiants

pubmed: 33495549
doi: 10.1038/s41429-021-00406-5
pii: 10.1038/s41429-021-00406-5
doi:

Substances chimiques

Anti-Bacterial Agents 0
Bridged Bicyclo Compounds, Heterocyclic 0
Diterpenes 0
Gels 0
Pore Forming Cytotoxic Proteins 0
retapamulin 4MG6O8991R
Fusidic Acid 59XE10C19C

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

337-345

Références

Fernandes P, Martens E. Antibiotics in late clinical development. Biochem Pharm. 2017;133:152–63.
pubmed: 27687641 doi: 10.1016/j.bcp.2016.09.025
Tacconelli E, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–27.
pubmed: 29276051 doi: 10.1016/S1473-3099(17)30753-3
Cassini A, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19:56–66.
pubmed: 30409683 pmcid: 6300481 doi: 10.1016/S1473-3099(18)30605-4
Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PLoS ONE. 2017;12:e0189621.
pubmed: 29267306 pmcid: 5739407 doi: 10.1371/journal.pone.0189621
Tacconelli E, Pezzani MD. Public health burden of antimicrobial resistance in Europe. Lancet Infect Dis. 2019;19:4–6.
pubmed: 30409682 doi: 10.1016/S1473-3099(18)30648-0
Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist. 2019;12:3903–10.
pubmed: 31908502 pmcid: 6929930 doi: 10.2147/IDR.S234610
Hofer U. The cost of antimicrobial resistance. Nat Rev Microbiol. 2019;17:3.
pubmed: 30467331 doi: 10.1038/s41579-018-0125-x
Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415:389–95.
pubmed: 11807545 doi: 10.1038/415389a
Mahlapuu M, Håkansson J, Ringstad L, Björn C. Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol. 2016;6:194.
pubmed: 28083516 pmcid: 5186781 doi: 10.3389/fcimb.2016.00194
Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev. 2003;55:27–55.
pubmed: 12615953 doi: 10.1124/pr.55.1.2
Svendsen JSM, Grant TM, Rennison D, Brimble MA, Svenson J. Very short and stable lactoferricin-derived antimicrobial peptides: design principles and potential uses. Acc Chem Res. 2019;52:749–59.
pubmed: 30829472 doi: 10.1021/acs.accounts.8b00624
Molchanova N, Hansen PR, Franzyk H. Advances in development of antimicrobial peptidomimetics as potential drugs. Molecules. 2017;22:1430.
pmcid: 6151827 doi: 10.3390/molecules22091430
Strøm MB, et al. The pharmacophore of short cationic antibacterial peptides. J Med Chem. 2003;46:1567–70.
pubmed: 12699374 doi: 10.1021/jm0340039
Flaten GE, et al. In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem. 2011;54:2422–32.
pubmed: 21401113 doi: 10.1021/jm1015704
Svenson J, et al. Altered activity and physicochemical properties of short cationic antimicrobial peptides by incorporation of arginine analogues. Mol Pharm. 2009;6:996–1005.
pubmed: 19341291 doi: 10.1021/mp900057k
Karstad R, et al. Targeting the S1 and S3 subsite of trypsin with unnatural cationic amino acids generates antimicrobial peptides with potential for oral administration. J Med Chem. 2012;55:6294–305.
pubmed: 22720778 doi: 10.1021/jm3002058
Svenson J, et al. Antimicrobial peptides with stability toward tryptic degradation. Biochemistry. 2008;47:3777–88.
pubmed: 18307313 doi: 10.1021/bi7019904
Svenson J, et al. Metabolic fate of lactoferricin-based antimicrobial peptides: effect of truncation and incorporation of amino acid analogs on the in vitro metabolic stability. J Pharm Exp Ther. 2010;332:1032–9.
doi: 10.1124/jpet.109.162826
Svenson J, Brandsdal BO, Stensen W, Svendsen JS. Albumin binding of short cationic antimicrobial micropeptides and its influence on the in vitro bactericidal effect. J Med Chem. 2007;50:3334–9.
pubmed: 17569519 doi: 10.1021/jm0703542
Lei J, et al. The antimicrobial peptides and their potential clinical applications. Am J Transl Res. 2019;11:3919.
pubmed: 31396309 pmcid: 6684887
Mishra B, Narayana JL, Lushnikova T, Wang X, Wang G. Low cationicity is important for systemic in vivo efficacy of database-derived peptides against drug-resistant Gram-positive pathogens. Proc Natl Acad Sci. 2019;116:13517–22.
pubmed: 31209048 doi: 10.1073/pnas.1821410116
Greco I, et al. Correlation between hemolytic activity, cytotoxicity and systemic in vivo toxicity of synthetic antimicrobial peptides. Sci Rep. 2020;10:13206.
pubmed: 32764602 pmcid: 7414031 doi: 10.1038/s41598-020-69995-9
Di L. Strategic approaches to optimizing peptide ADME properties. AAPS J. 2015;17:134–43.
pubmed: 25366889 doi: 10.1208/s12248-014-9687-3
Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol. 2008;122:261–6.
pubmed: 18439663 pmcid: 2639779 doi: 10.1016/j.jaci.2008.03.027
Fellermann K, Wehkamp J, Stange EF. Antimicrobial peptides in the skin. N Engl J Med. 2003;348:361–3.
pubmed: 12540655 doi: 10.1056/NEJM200301233480418
Schittek B, Paulmann M, Senyurek I, Steffen H. The role of antimicrobial peptides in human skin and in skin infectious diseases. Infect Disord Drug Targets. 2008;8:135–43.
pubmed: 18782030 doi: 10.2174/1871526510808030135
Woodburn KW, Jaynes J, Clemens LE. Designed antimicrobial peptides for topical treatment of antibiotic resistant Acne vulgaris. Antibiotics. 2020;9:23.
pmcid: 7168327 doi: 10.3390/antibiotics9010023
Woodburn KW, Jaynes JM, Clemens LE. Evaluation of the antimicrobial peptide, RP557, for the broad-spectrum treatment of wound pathogens and biofilm. Front Microbiol. 2019;10:1688.
pubmed: 31396193 pmcid: 6667648 doi: 10.3389/fmicb.2019.01688
Thapa RK, Diep DB, Tønnesen HH. Topical antimicrobial peptide formulations for wound healing: current developments and future prospects. Acta Biomater. 2020;103:52–67.
pubmed: 31874224 doi: 10.1016/j.actbio.2019.12.025
Stulberg DL, Penrod MA, Blatny RA. Common bacterial skin infections. Am Fam Physician. 2002;66:119–25.
pubmed: 12126026
Kaye KS, Petty LA, Shorr AF, Zilberberg MD. Current epidemiology, etiology, and burden of acute skin infections in the United States. Clin Infect Dis. 2019;68:193–9.
doi: 10.1093/cid/ciz002
Lee G, Boyd N, Lawson K, Frei C. Incidence and cost of skin and soft tissue infections in the United States. Value Health. 2015;18:A245.
doi: 10.1016/j.jval.2015.03.1424
Strøm MB, et al. Important structural features of 15-residue lactoferricin derivatives and methods for improvement of antimicrobial activity. Biochem Cell Biol. 2002;80:65–74.
pubmed: 11908644 doi: 10.1139/o01-236
Haug BE, Stensen W, Kalaaji M, Rekdal Ø, Svendsen JS. Synthetic antimicrobial peptidomimetics with therapeutic potential. J Med Chem. 2008;51:4306–14.
pubmed: 18570363 doi: 10.1021/jm701600a
Haug BE, Skar ML, Svendsen JS. Bulky aromatic amino acids increase the antibacterial activity of 15‐residue bovine lactoferricin derivatives. J Pep Sci. 2001;7:425–32.
doi: 10.1002/psc.338
Haug BE, Strom M, Svendsen M. The medicinal chemistry of short lactoferricin-based antibacterial peptides. Curr Med Chem. 2007;14:1–18.
pubmed: 17266565 doi: 10.2174/092986707779313435
Karstad R, Isaksen G, Brandsdal B-O, Svendsen JS, Svenson J. Unnatural amino acid side chains as S1, S1′, and S2′ probes yield cationic antimicrobial peptides with stability toward chymotryptic degradation. J Med Chem. 2010;53:5558–66.
pubmed: 20608742 doi: 10.1021/jm1006337
Saravolatz LD, et al. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2012;56:4478–82.
pubmed: 22585222 pmcid: 3421571 doi: 10.1128/AAC.00194-12
Stensen W, et al. Short cationic antimicrobial peptides display superior antifungal activities toward candidiasis and onychomycosis in comparison with terbinafine and amorolfine. Mol Pharm. 2016;13:3595–600.
pubmed: 27576445 doi: 10.1021/acs.molpharmaceut.6b00654
Fernandes KE, Payne RJ, Carter DA. Lactoferrin-derived peptide lactofungin is potently synergistic with amphotericin B. Antimicrob Agents Chemother. 2020;64:e00842-20
pubmed: 32690642 pmcid: 7508585 doi: 10.1128/AAC.00842-20
Nilsson AC, et al. LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and-sensitive Staphylococcus aureus. Antimicrob Agents Chemother. 2015;59:145–51.
pubmed: 25331699 doi: 10.1128/AAC.03513-14
Kugelberg E, et al. Establishment of a superficial skin infection model in mice by using Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother. 2005;49:3435–41.
pubmed: 16048958 pmcid: 1196267 doi: 10.1128/AAC.49.8.3435-3441.2005
Scaramuzzino DA, McNiff JM, Bessen DE. Humanized in vivo model for Streptococcal impetigo. Infect Immun. 2000;68:2880–7.
pubmed: 10768985 pmcid: 97500 doi: 10.1128/IAI.68.5.2880-2887.2000
Yu G, Baeder DY, Regoes RR, Rolff J. Combination effects of antimicrobial peptides. Antimicrob Agents Chemother. 2016;60:1717–24.
pubmed: 26729502 pmcid: 4775937 doi: 10.1128/AAC.02434-15
Håkansson J, et al. Efficacy of the novel topical antimicrobial agent PXL150 in a mouse model of surgical site infections. Antimicrob Agents Chemother. 2014;58:2982–4.
pubmed: 24590479 pmcid: 3993255 doi: 10.1128/AAC.00143-14
Haisma EM, et al. Antimicrobial peptide P60. 4Ac-containing creams and gel for eradication of methicillin-resistant Staphylococcus aureus from cultured skin and airway epithelial surfaces. Antimicrob Agents Chemother. 2016;60:4063–72.
pubmed: 27114278 pmcid: 4914645 doi: 10.1128/AAC.03001-15
Jones V, Grey JE, Harding KG. Wound dressings. BMJ. 2006;332:777–80.
pubmed: 16575081 pmcid: 1420733 doi: 10.1136/bmj.332.7544.777
Isaksson J, et al. A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011;54:5786–95.
pubmed: 21732630 doi: 10.1021/jm200450h
Mortensen B, Fugelli A, Olsen W, editors. Evaluation of the preclinical safety and tolerability profile of LTX-109 a novel antimicrobial drug. Abstr 51st interscience conference on antimicrobial agents and chemotherapy. American Society for Microbiology, Boston, MA; 2011.
Pfalzgraff A, Brandenburg K, Weindl G. Antimicrobial peptides and their therapeutic potential for bacterial skin infections and wounds. Front Pharmacol. 2018;9:281.
Mahlapuu M, Björn C, Ekblom J. Antimicrobial peptides as therapeutic agents: opportunities and challenges. Crit Rev Biotechnol. 2020;40:978–92.
pubmed: 32781848 doi: 10.1080/07388551.2020.1796576
Björn C, et al. Efficacy and safety profile of the novel antimicrobial peptide PXL150 in a mouse model of infected burn wounds. Int J Antimicrob Agents. 2015;45:519–24.
pubmed: 25649371 doi: 10.1016/j.ijantimicag.2014.12.015
Myhrman E, et al. The novel antimicrobial peptide PXL150 in the local treatment of skin and soft tissue infections. Appl Microbiol Biotechnol. 2013;97:3085–96.
pubmed: 23053090 doi: 10.1007/s00253-012-4439-8
Li Z, et al. K1K8: an Hp1404-derived antibacterial peptide. Appl Microbiol Biotechnol. 2016;100:5069–77.
pubmed: 26952110 doi: 10.1007/s00253-016-7395-x
Liu S, et al. Assessment of antimicrobial and wound healing effects of Brevinin-2Ta against the bacterium Klebsiella pneumoniae in dermally-wounded rats. Oncotarget. 2017;8:111369–85.
pubmed: 29340060 pmcid: 5762328 doi: 10.18632/oncotarget.22797
Jacobsen F, et al. Antimicrobial activity of the recombinant designer host defence peptide P-novispirin G10 in infected full-thickness wounds of porcine skin. J Antimicrob Chemother. 2007;59:493–8.
pubmed: 17289767 doi: 10.1093/jac/dkl513

Auteurs

Joakim Håkansson (J)

Department of Chemistry, Biomaterial & Textile, RISE Research Institutes of Sweden, Borås, Sweden.
Department of Laboratory Medicine, Institute of Biomedicine, Gothenburg University, Gothenburg, Sweden.

Jorunn Pauline Cavanagh (JP)

Amicoat A/S, Sandvika, Norway.
Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.

Wenche Stensen (W)

Department of Chemistry, UiT The Arctic University of Norway, Tromsø, Norway.

Bjarte Mortensen (B)

Amicoat A/S, Sandvika, Norway.

John-Sigurd Svendsen (JS)

Amicoat A/S, Sandvika, Norway.
Department of Chemistry, UiT The Arctic University of Norway, Tromsø, Norway.

Johan Svenson (J)

Department of Chemistry, Biomaterial & Textile, RISE Research Institutes of Sweden, Borås, Sweden. johan.svenson@cawthron.org.nz.
Cawthron Institute, Nelson, New Zealand. johan.svenson@cawthron.org.nz.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH